Hansoh Pharma Reshuffles Company Secretariat: New Joint Company Secretary and Authorized Representative Appointed

Bulletin Express05-15

Hansoh Pharmaceutical Group Company Limited (Hansoh Pharma) has announced a series of senior corporate governance changes effective 15 May 2026.

Mr. Lee Leong Yin has resigned from his positions as joint company secretary, authorized representative under Listing Rule 3.05 and process agent in Hong Kong, citing personal work arrangements. The Board confirmed that Mr. Lee has no disagreements with the directors and no matters requiring shareholder or exchange attention.

To ensure continuity, the Board has appointed Ms. Zeng Zhao—currently a Senior Manager of Company Secretarial Services at Tricor Services Limited with more than ten years of relevant experience—as joint company secretary. Ms. Zeng meets the professional qualifications stipulated in Listing Rule 3.28.

With Ms. Zeng’s appointment, Hansoh Pharma’s company secretarial structure is as follows: • Joint Company Secretaries: Ms. Zhong Shengli and Ms. Zeng Zhao • Authorized Representatives (Listing Rule 3.05): Ms. Sun Yuan and Ms. Zeng Zhao • Process Agents (Companies Ordinance, Part 16): Ms. Sun Yuan and Ms. Zeng Zhao

The Board, chaired by Ms. Zhong Huijuan, now comprises three executive directors—Ms. Zhong Huijuan, Ms. Sun Yuan and Dr. Lyu Aifeng—alongside four independent non-executive directors: Mr. Lin Guoqiang, Mr. Chan Charles Sheung Wai, Ms. Yang Dongtao and Mr. Yan Jia.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment